Hugh Alsop

Kinoxis Therapeutics closes $6.75 million financing round

Melbourne biotech Kinoxis completed a $6.75 million round with new backer MainSequence and won a $2.5 million government-funded CUREator+ grant for dementia and pain drug development; MainSequence's Elaine Stead joins the board.

Also Startup Daily·Startup Daily·Dealroom·This Week in Australian Startups·Dynamic Business

Five ANZ startups that raised $38.5 million this week

Weekly roundup detailing five raises across Australian and New Zealand startups — Hapana, Kinoxis Therapeutics, Appetise, Bike Matrix and Aglow — worth a combined $38.5 million, naming lead investors and planned expansion for each.

Also SmartCompany·Startup Daily

Kinoxis secures $14.5m in funding and announces expansion of clinical programs to target agitation and aggression in dementia patients

Australian biotech Kinoxis Therapeutics raised $14.5 million in Series B backing from Uniseed, UniSuper and others to fund Phase 2 trials of KNX100 for dementia-related agitation, including a new Australian study.

Also SmartCompany·Startup Daily·Startup Daily

GBS Ventures achieves its 4th New Drug Approval from the US FDA

GBS Ventures marks its fourth FDA drug approval as Hatchtech's head lice treatment Xeglyze clears the regulator, recalling earlier wins behind Picato, Synribo and Aridol with Australian biotech firms.

FDA Approves Xeglyze™ for the topical treatment of head lice infestation

HATCHTECH RECEIVES FDA SPECIAL PROTOCOL AGREEMENT OF DEOVO PHASE III STUDIES

Hatchtech announced FDA sign-off on its DeOvo Phase 3 trials and two extra patents; its profile names GBS Venture Partners among the company's investors.

HATCHTECH COMPLETES $12.6M CAPITAL RAISE

Melbourne drug developer Hatchtech raised A$12.6 million, with OneVentures Innovation Fund leading, to advance its head lice treatment toward Phase III trials; board changes brought in Richard Treagus and Hugh Alsop.